{"id":2652,"date":"2018-05-17T17:26:41","date_gmt":"2018-05-17T11:56:41","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2652"},"modified":"2021-07-24T12:56:59","modified_gmt":"2021-07-24T07:26:59","slug":"zymeworks-business-cocktail-18","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/zymeworks-business-cocktail-18","title":{"rendered":"Business Cocktail"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Zymeworks Daiichi I-O deal could potentially be worth USD 485 million<\/strong><\/p>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/www.zymeworks.com\/\"><strong>Zymeworks<\/strong><\/a> and <a href=\"https:\/\/www.daiichisankyo.com\/\"><strong>Daiichi Sankyo<\/strong><\/a> teamed up in 2016 on bispecific antibodies at that time the financial details were kept under the curtains. The pair is now entering into a new license agreement with a potential deal worth of around <strong>USD 484.7 million<\/strong>. The new agreement will grant the Japanese pharma two more licenses for an upfront technology access fee of USD 18 million as per the reports.<\/p>\n<p style=\"text-align: justify;\"><strong>Celsius grabs USD 65 million funding to develop precision drugs for cancer, autoimmune disease<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Celsius Therapeutics<\/strong> is all set to develop single-cell genomic sequencing based therapeutics. After bagging <strong>USD 65 million<\/strong> in series A funding, the venture will\u00a0now sequence defined patient samples for identifying the individual cells responsible for disease. Company is hoping to bring forth the first ever precision medicines for curing the autoimmune disease.<\/p>\n<p style=\"text-align: justify;\"><strong>MeiraGTx files for USD 86 million IPO <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>MeiraGTx<\/strong>, a gene therapy based startup has\u00a0filed\u00a0for <strong>USD 86 million<\/strong> IPO to push some of its gene therapies into the clinical trials. Company is initially targeting inherited retinal diseases with therapies that are designed to stop\/pause vision loss.<\/p>\n<p style=\"text-align: justify;\"><strong>EIP Pharma bags USD 20.5 million in series B funding to push Alzheimer&#8217;s drug through phase 2<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>EIP Pharma<\/strong> has recently bagged <strong>USD 20.5 million<\/strong> in series B funding to support the <a href=\"https:\/\/www.delveinsight.com\/report-store\/dementia-associated-with-alzheimers-disease-pipeline-insight\">Alzheimer&#8217;s <\/a>treatment, <strong>neflamapimod<\/strong> that is currently in the <strong>phase 2b<\/strong> of development. The funding will also help in building up its team and support the search of other <strong>CNS disorders<\/strong> for which the drug might be useful.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zymeworks Daiichi I-O deal could potentially be worth USD 485 million Zymeworks and Daiichi Sankyo teamed up in 2016 on bispecific antibodies at that time the financial details were kept under the curtains. The pair is now entering into a new license agreement with a potential deal worth of around USD 484.7 million. The new [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2290,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[776,1636,1640,1155,1635,204,1638,349,1637,1639,1261,706,1634],"industry":[17225],"therapeutic_areas":[17227,17245,17228],"class_list":["post-2652","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-business-cocktail","tag-celsius-therapeutics","tag-cns-disorders","tag-consultancy","tag-daiichi-sankyo","tag-delveinsight","tag-eip-pharma","tag-latest-pharma-news","tag-meiragtx","tag-neflamapimod","tag-pharma-consulting","tag-pharmaceutical-industry","tag-zymeworks","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ZYMEWORKS(Business Cocktail) - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Zymeworks and Daiichi Sankyo teamed up in 2016 on bispecific antibodies at that time the financial details were kept under the curtains.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/zymeworks-business-cocktail-18\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ZYMEWORKS(Business Cocktail) - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Zymeworks and Daiichi Sankyo teamed up in 2016 on bispecific antibodies at that time the financial details were kept under the curtains.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/zymeworks-business-cocktail-18\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-17T11:56:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"620\" \/>\n\t<meta property=\"og:image:height\" content=\"414\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ZYMEWORKS(Business Cocktail) - DelveInsight Business Research","description":"Zymeworks and Daiichi Sankyo teamed up in 2016 on bispecific antibodies at that time the financial details were kept under the curtains.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/zymeworks-business-cocktail-18","og_locale":"en_US","og_type":"article","og_title":"ZYMEWORKS(Business Cocktail) - DelveInsight Business Research","og_description":"Zymeworks and Daiichi Sankyo teamed up in 2016 on bispecific antibodies at that time the financial details were kept under the curtains.","og_url":"https:\/\/www.delveinsight.com\/blog\/zymeworks-business-cocktail-18","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-05-17T11:56:41+00:00","article_modified_time":"2021-07-24T07:26:59+00:00","og_image":[{"width":620,"height":414,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/zymeworks-business-cocktail-18","url":"https:\/\/www.delveinsight.com\/blog\/zymeworks-business-cocktail-18","name":"ZYMEWORKS(Business Cocktail) - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/zymeworks-business-cocktail-18#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/zymeworks-business-cocktail-18#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","datePublished":"2018-05-17T11:56:41+00:00","dateModified":"2021-07-24T07:26:59+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Zymeworks and Daiichi Sankyo teamed up in 2016 on bispecific antibodies at that time the financial details were kept under the curtains.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/zymeworks-business-cocktail-18"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/zymeworks-business-cocktail-18#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","width":620,"height":414,"caption":"Entasis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing-300x200.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Business Cocktail<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Celsius Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CNS disorders<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Daiichi Sankyo<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">EIP Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MeiraGTx<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">neflamapimod<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Zymeworks<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Business Cocktail<\/span>","<span class=\"advgb-post-tax-term\">Celsius Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">CNS disorders<\/span>","<span class=\"advgb-post-tax-term\">consultancy<\/span>","<span class=\"advgb-post-tax-term\">Daiichi Sankyo<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">EIP Pharma<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">MeiraGTx<\/span>","<span class=\"advgb-post-tax-term\">neflamapimod<\/span>","<span class=\"advgb-post-tax-term\">pharma consulting<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/span>","<span class=\"advgb-post-tax-term\">Zymeworks<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on May 17, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on May 17, 2018 5:26 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2652","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2652"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2652\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2290"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2652"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2652"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2652"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2652"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2652"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}